AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
Log in

NASDAQ:PRQRProQR Therapeutics News Headlines

$4.99
+0.01 (+0.20 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.91
Now: $4.99
$5.21
50-Day Range
$4.98
MA: $5.68
$6.46
52-Week Range
$4.46
Now: $4.99
$10.98
Volume129,526 shs
Average Volume191,334 shs
Market Capitalization$248.23 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52

Headlines

ProQR Therapeutics (NASDAQ PRQR) News Headlines

Source:
DateHeadline
ProQR Therapeutics NV (NASDAQ:PRQR) Given Average Rating of "Buy" by AnalystsProQR Therapeutics NV (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 10 at 1:38 AM
ProQR Therapeutics (NASDAQ:PRQR) Cut to "Sell" at BidaskClubProQR Therapeutics (NASDAQ:PRQR) Cut to "Sell" at BidaskClub
www.marketbeat.com - July 7 at 1:14 AM
News Flash: Analysts Just Made A Stunning Upgrade To Their ProQR Therapeutics N.V. (NASDAQ:PRQR) ForecastsNews Flash: Analysts Just Made A Stunning Upgrade To Their ProQR Therapeutics N.V. (NASDAQ:PRQR) Forecasts
finance.yahoo.com - June 29 at 9:33 AM
ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Reaffirmed by Chardan CapitalProQR Therapeutics (NASDAQ:PRQR) Stock Rating Reaffirmed by Chardan Capital
www.americanbankingnews.com - June 24 at 7:00 AM
Hedge Funds Souring On ProQR Therapeutics NV (PRQR)Hedge Funds Souring On ProQR Therapeutics NV (PRQR)
finance.yahoo.com - June 22 at 7:35 PM
5 Must-Buy Low-Beta Stocks Flying High in a Volatile Market5 Must-Buy Low-Beta Stocks Flying High in a Volatile Market
finance.yahoo.com - June 22 at 9:31 AM
Zacks.com featured highlights include: Frontline, iClick Interactive Asia, Avenue Therapeutics, ProQR Therapeutics and BJ???s Wholesale ClubZacks.com featured highlights include: Frontline, iClick Interactive Asia, Avenue Therapeutics, ProQR Therapeutics and BJ???s Wholesale Club
finance.yahoo.com - June 18 at 8:51 PM
ProQR Therapeutics NV (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from AnalystsProQR Therapeutics NV (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 15 at 1:53 AM
ProQR Announces Expert Perspectives Conference Call SeriesProQR Announces Expert Perspectives Conference Call Series
finance.yahoo.com - June 12 at 7:49 AM
BRIEF-ProQR Announces Virtual Presentation Of Phase 1/2 Sepofarsen DataBRIEF-ProQR Announces Virtual Presentation Of Phase 1/2 Sepofarsen Data
www.reuters.com - June 8 at 12:55 PM
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)
finance.yahoo.com - June 8 at 7:48 AM
How ProQR (PRQR) Stock Stands Out in a Strong IndustryHow ProQR (PRQR) Stock Stands Out in a Strong Industry
finance.yahoo.com - May 29 at 1:39 PM
BRIEF-ProQR Therapeutics Announces First Quarter 2020 Financial ResultsBRIEF-ProQR Therapeutics Announces First Quarter 2020 Financial Results
www.reuters.com - May 7 at 4:02 PM
ProQR Announces First Quarter 2020 Operating and Financial ResultsProQR Announces First Quarter 2020 Operating and Financial Results
finance.yahoo.com - May 7 at 4:02 PM
ProQR (PRQR) Reports Q1 Loss, Lags Revenue EstimatesProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 7 at 4:02 PM
Does ProQR Therapeutics (NASDAQ:PRQR) Have A Healthy Balance Sheet?Does ProQR Therapeutics (NASDAQ:PRQR) Have A Healthy Balance Sheet?
finance.yahoo.com - April 28 at 10:04 AM
ProQR Therapeutics N.V.ProQR Therapeutics N.V.
www.marketwatch.com - April 25 at 11:39 PM
Covid-19 pandemic to impact timelines for ProQR Therapeuticss pipeline; announces interim analysis from Phase 1/2 trial of QR-421aCovid-19 pandemic to impact timelines for ProQR Therapeutics's pipeline; announces interim analysis from Phase 1/2 trial of QR-421a
seekingalpha.com - March 31 at 5:17 PM
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business UpdateProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
finance.yahoo.com - March 31 at 8:19 AM
ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher SyndromeProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
finance.yahoo.com - March 25 at 5:55 PM
How Much Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Pocket Last Year?How Much Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Pocket Last Year?
finance.yahoo.com - February 28 at 3:17 PM
ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business UpdateProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update
finance.yahoo.com - February 26 at 8:03 AM
ProQR to Present at Cowen and Company 40th Annual Health Care ConferenceProQR to Present at Cowen and Company 40th Annual Health Care Conference
finance.yahoo.com - February 24 at 8:39 AM
Stock To Watch: ProQR Therapeutics (PRQR)Stock To Watch: ProQR Therapeutics (PRQR)
www.nasdaq.com - February 11 at 2:56 PM
My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S.My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S.
www.globenewswire.com - February 6 at 9:31 AM
ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal DiseasesProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases
finance.yahoo.com - February 6 at 9:31 AM
ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421aProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a
finance.yahoo.com - January 30 at 9:33 AM
Did Business Growth Power ProQR Therapeuticss (NASDAQ:PRQR) Share Price Gain of 119%?Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 119%?
finance.yahoo.com - December 23 at 4:14 PM
Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 119%?Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 119%?
finance.yahoo.com - December 23 at 4:14 PM
Did Hedge Funds Drop The Ball On ProQR Therapeutics NV (PRQR) ?Did Hedge Funds Drop The Ball On ProQR Therapeutics NV (PRQR) ?
finance.yahoo.com - December 17 at 6:19 PM
Dosing underway in study of ProQRs QR-1123 for vision loss disorderDosing underway in study of ProQR's QR-1123 for vision loss disorder
seekingalpha.com - December 11 at 1:16 PM
ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis PigmentosaProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
finance.yahoo.com - December 11 at 8:15 AM
Moderna: Undervalued As The Promising Pipeline Awaits CollaborationsModerna: Undervalued As The Promising Pipeline Awaits Collaborations
seekingalpha.com - November 21 at 7:53 PM
ProQR Therapeutics Takes a Big Step Forward With Its Latest FDA ApprovalProQR Therapeutics Takes a Big Step Forward With Its Latest FDA Approval
www.msn.com - November 21 at 9:34 AM
ProQR Therapeutics on watch after FDA winProQR Therapeutics on watch after FDA win
seekingalpha.com - November 21 at 9:34 AM
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis PigmentosaProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
finance.yahoo.com - November 21 at 9:34 AM
ProQR shares rises on FDA orphan drug designationProQR shares rises on FDA orphan drug designation
finance.yahoo.com - November 21 at 9:34 AM
ProQR to Present at Upcoming Scientific ConferencesProQR to Present at Upcoming Scientific Conferences
finance.yahoo.com - November 18 at 8:20 AM
ProQR to Present at Upcoming Investor ConferencesProQR to Present at Upcoming Investor Conferences
finance.yahoo.com - November 13 at 8:42 AM
Biotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, AgiosBiotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, Agios
www.thestreet.com - November 8 at 11:41 PM
ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
finance.yahoo.com - November 6 at 8:52 AM
Will ProQR Therapeutics Continue to Surge Higher?Will ProQR Therapeutics Continue to Surge Higher?
finance.yahoo.com - October 23 at 10:52 AM
ProQR prices stock offering; shares down 12% after hoursProQR prices stock offering; shares down 12% after hours
seekingalpha.com - October 16 at 12:20 AM
ProQR Prices $50 Million Underwritten Public Offering of Ordinary SharesProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
finance.yahoo.com - October 16 at 12:20 AM
ProQRs sepofarsen nabs Rare Pediatric Disease status in U.S. for LCA10ProQR's sepofarsen nabs Rare Pediatric Disease status in U.S. for LCA10
seekingalpha.com - October 15 at 7:19 PM
ProQR Therapeutics (PRQR) Sepofarsen Phase 1/2 Trial Topline Results - SlideshowProQR Therapeutics (PRQR) Sepofarsen Phase 1/2 Trial Topline Results - Slideshow
seekingalpha.com - October 11 at 6:44 PM
ProQR Therapeutics N.V.: ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 PatientsProQR Therapeutics N.V.: ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
www.finanznachrichten.de - October 10 at 7:26 AM
ProQRs sepofarsen shows positive action in Phase 1/2 study in LCA10ProQR's sepofarsen shows positive action in Phase 1/2 study in LCA10
seekingalpha.com - October 10 at 7:26 AM
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 PatientsProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
finance.yahoo.com - October 10 at 7:26 AM
ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAOProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO
finance.yahoo.com - October 7 at 9:04 AM
This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.